Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs published in the peer reviewed journal, Biomedicines.
Design for Thykamine™ Phase 2/3 clinical study in pediatric Atopic Dermatitis is complete based on the positive results of the phase 2 in an adult population.
Thykamine™ radiodermatitis pivotal clinical study in the process of being initiated.
First quarter gross margin on distribution revenues of $0.5 million
First quarter net loss of $1.6 million dollars, ($0.01) per share
Private placements completed with gross proceeds of $2.7 million
Cash as of October 31, 2025 of $6.6 million; Company remains debt free
QUÉBEC, Dec. 12, 2025 /CNW/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV:GSD) (OTCQB:DVHGF), today announced operating and financial results for its first quarter ended on October 31, 2025.
Management Comments
''We are very pleased with the continued momentum across both our therapeutic and commercial activities this quarter. Thykamine™'s progress in preclinical MASH and fibrosis strengthens its profile as a promising first-in-class anti-inflammatory candidate, while the readiness of our Phase 2/3 pediatric atopic dermatitis study marks an important milestone toward addressing a significant unmet medical need. Our gross margin performance, combined with the successful completion of $2.7 million in private placements, reflects growing confidence in our strategy and in the long-term value of our pipeline'' said Dr Andre Boulet, PhD, Chief Executive Officer of Devonian.
Business Highlights
The Company finalized the protocol for a 12-week, multicenter, randomized, double-blind, vehicle-controlled, Phase 2/3 clinical study investigating the safety and efficacy of two strengths. (0.05% and 0.1%) of PUR 0110 (Thykamine™) Cream applied twice daily to pediatric patients (3 months to 17 years of age) with mild to moderate atopic dermatitis (the "Pediatric AD clinical study"). The study is ready to be initiated following approval by regulatory agencies.
The Company is preparing its pivotal clinical study of Thykamine™ for radiodermatitis. It will be a double-blind, randomized, Glaxal-based, controlled multicenter study in patients with breast cancer.
Preclinical studies are ongoing to highlight the potential of ...
